查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089773

HPV相關疾病市場規模、佔有率和趨勢分析報告：按類型、療法、分銷管道、地區和細分市場預測（2026-2033年）

HPV Associated Disorders Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

HPV相關疾病市場概述

2025 年全球 HPV 相關疾病市場價值為 194 億美元，預計從 2026 年到 2033 年將以 4.9% 的複合年成長率成長，到 2033 年達到 204 億美元至 285 億美元。

2025年，北美HPV相關疾病市場將佔據全球市場最大佔有率，達37.4%。由於HPV持續感染與子宮頸癌、肛門癌、外陰癌、陰道癌、陰莖癌和口咽癌密切相關，因此，HPV持續感染在HPV相關疾病市場中仍構成重大的臨床和經濟負擔。

隨著HPV相關惡性腫瘤發生率的不斷上升，全球醫療系統對早期、精準診斷解決方案的需求日益成長。因此，能夠檢測高危險型HPV病毒株（尤其是HPV-16和HPV-18）的分子診斷技術正被醫院、癌症中心和專業實驗室廣泛採用。醫療衛生機構也正在加強系統性篩檢措施，以促進癌前病變的早期發現，並減輕癌症的長期負擔。此外，人們對HPV相關癌症的認知不斷提高，以及「HPV優先」篩檢方案的廣泛應用，正在推動已開發國家和新興國家醫療衛生市場的檢測量增加。這些趨勢持續凸顯了預防性診斷和及時疾病管理在全球HPV相關疾病市場的重要性。

治療技術的進步正成為HPV相關疾病市場另一大成長要素。尤其值得一提的是，針對HPV相關惡性腫瘤的免疫療法、標靶抗癌藥物和精準醫療方法正蓬勃發展。製藥和生技公司正加大研發投入，以強化其治療產品線，並改善持續性HPV相關癌症患者的治療效果。評估免疫檢查查核點抑制劑、治療性疫苗和基於生物標記的療法的臨床試驗在延長無惡化生存期和降低復發率方面顯示出令人鼓舞的結果。此外，對個人化癌症治療策略的日益重視也促進了標靶治療在HPV相關子宮頸癌和頭頸癌治療中的廣泛應用。這些創新措施滿足了尚未滿足的醫療需求，同時改善了疾病的長期管理和患者的生活品質，從而為從事HPV相關疾病治療的公司創造了巨大的成長機會。

例如，2025年4月，BioMed Central Ltd.的作者報告稱，DNA病毒人類乳突病毒（HPV）已被證實是子宮頸癌、外陰癌、陰道癌、陰莖癌、肛門癌以及頭頸癌的致病因素。研究強調，特定HPV基因型的持續感染和致癌活性是全球大多數HPV相關惡性腫瘤的罪魁禍首。據通報，HPV-16和HPV-18等高危險型HPV在全球子宮頸癌病例中佔比超過70%，已被證實對生殖器癌和口咽癌有顯著影響。在分子層面上，研究發現E6和E7致癌蛋白的過度表現是破壞細胞週期調控並促進惡性腫瘤發生的主要機制。此外，該綜述重點介紹了生物標記（包括 mRNA、miRNA、lncRNA、蛋白質和遺傳標記）的最新進展，這些標記可用於監測治療反應，並支持 HPV 相關癌症的精準腫瘤學方法。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：HPV相關疾病市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：HPV相關疾病市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 子宮頸上皮內瘤（CIN）
  • 子宮頸癌
  • 肛門上皮內瘤（AIN）
  • 肛門癌
  • 生殖器疣
  • 其他

第5章：HPV相關疾病市場：按療法分類的業務分析

  • 按治療方法分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療方法分類，2021-2033 年
  • 疫苗
  • 抗病毒藥物
  • 其他

第6章：HPV相關疾病市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 其他

第7章：HPV相關疾病市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • AstraZeneca
    • Biocon
    • Lilly
    • AbbVie Inc.
Product Code: GVR-3-68038-436-9

HPV Associated Disorders Market Summary

The global HPV associated disorders market size was valued at USD 19.4 billion in 2025 and is projected to grow from USD 20.4 billion to USD 28.5 billion by 2033, at a CAGR of 4.9% from 2026 to 2033. North America HPV associated disorders market held the largest share of 37.4% of the global market in 2025. Persistent HPV infections continue to represent a major clinical and economic burden within the HPV associated disorders market, as they are strongly linked to cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers.

The increasing incidence of HPV-driven malignancies is accelerating demand for early and accurate diagnostic solutions across healthcare systems globally. As a result, molecular diagnostic technologies capable of detecting high-risk HPV strains, particularly HPV-16 and HPV-18, are witnessing rising adoption in hospitals, cancer centers, and specialized laboratories. Healthcare authorities are also strengthening organized screening initiatives to improve early identification of precancerous lesions and reduce long-term cancer burden. In addition, growing awareness regarding HPV-associated cancers and rising implementation of HPV-first screening protocols are supporting higher testing volumes across developed and emerging healthcare markets. These trends continue to reinforce the importance of preventive diagnostics and timely disease management within the global HPV associated disorders market landscape.

Advancements in treatment solutions are emerging as another major growth driver for the HPV associated disorders market, particularly with increasing development of immunotherapies, targeted oncology drugs, and precision medicine approaches for HPV-related malignancies. Pharmaceutical and biotechnology companies are expanding research and development investments to strengthen the therapeutic pipeline and improve treatment outcomes for patients with persistent HPV-associated cancers. Clinical studies evaluating immune checkpoint inhibitors, therapeutic vaccines, and biomarker-driven therapies are yielding encouraging results in terms of progression-free survival and reduced recurrence. In addition, rising focus on personalized oncology treatment strategies is contributing to broader adoption of targeted therapies for cervical and head & neck cancers linked to HPV infection. These innovations are addressing unmet clinical needs while improving long-term disease management and patient quality of life, thereby creating significant growth opportunities for companies operating within the HPV associated disorders treatment landscape.

For instance, in April 2025, authors at BioMed Central Ltd. reported that human papillomavirus (HPV), a DNA virus, had been established as a causative agent of cervical, vulvar, vaginal, penile, anal, and head & neck cancers. The study highlighted that persistent infection and the oncogenic activity of specific HPV genotypes were responsible for the majority of HPV-related malignancies worldwide. High-risk strains such as HPV-16 and HPV-18 were reported to account for more than 70% of cervical cancer cases globally, while also contributing significantly to genital and oropharyngeal cancers. At the molecular level, the study identified overexpression of E6 and E7 oncoproteins as a key mechanism disrupting cell-cycle regulation and promoting malignant transformation. The review further emphasized recent advancements involving biomarkers, including mRNAs, miRNAs, lncRNAs, proteins, and genetic markers, for monitoring therapeutic response and supporting precision oncology approaches in HPV-related cancer management.

Global HPV Associated Disorders Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cervical Intraepithelial Neoplasia (CIN)
  • Cervical Cancer
  • Anal Intraepithelial Neoplasia (AIN)
  • Anal Cancer
  • Genital Warts
  • Others
  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
  • Vaccines
  • Anti-viral Drugs
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. HPV Associated Disorders Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. HPV Associated Disorders Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 4.4. Cervical Intraepithelial Neoplasia (CIN)
    • 4.4.1. Cervical Intraepithelial Neoplasia (CIN) Market, 2021 - 2033 (USD Billion)
  • 4.5. Cervical Cancer
    • 4.5.1. Cervical Cancer Market, 2021 - 2033 (USD Billion)
  • 4.6. Anal Intraepithelial Neoplasia (AIN)
    • 4.6.1. Anal Intraepithelial Neoplasia (AIN) Market, 2021 - 2033 (USD Billion)
  • 4.7. Anal Cancer
    • 4.7.1. Anal Cancer Market, 2021 - 2033 (USD Billion)
  • 4.8. Genital Warts
    • 4.8.1. Genital Warts Market, 2021 - 2033 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. HPV Associated Disorders Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
  • 5.4. Vaccines
    • 5.4.1. Vaccines Market, 2021 - 2033 (USD Billion)
  • 5.5. Anti-viral Drugs
    • 5.5.1. Anti-viral Drugs Market, 2021 - 2033 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. HPV Associated Disorders Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. HPV Associated Disorders Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America HPV Associated Disorders Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GlaxoSmithKline plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Pfizer Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Biocon
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Lilly
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. AbbVie Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global HPV associated disorders market, by region, 2021 - 2033 (USD Billion)
  • Table 4. Global HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 5. Global HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 6. Global HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 7. North America HPV associated disorders market, by country, 2021 - 2033 (USD Billion)
  • Table 8. North America HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 9. North America HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 10. North America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 11. U.S. HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 12. U.S. HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 13. U.S. HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 14. Canada HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 15. Canada HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 16. Canada HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17. Mexico HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 18. Mexico HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 19. Mexico HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 20. Europe HPV associated disorders market, by country, 2021 - 2033 (USD Billion)
  • Table 21. Europe HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 22. Europe HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 23. Europe HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 24. UK HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 25. UK HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 26. UK HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 27. Germany HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 28. Germany HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 29. Germany HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30. France HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 31. France HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 32. France HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 33. Italy HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 34. Italy HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 35. Italy HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 36. Spain HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 37. Spain HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 38. Spain HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 39. Norway HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 40. Norway HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 41. Norway HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42. Denmark HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 43. Denmark HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 44. Denmark HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 45. Sweden HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 46. Sweden HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 47. Sweden HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 48. Asia Pacific HPV associated disorders market, by country, 2021 - 2033 (USD Billion)
  • Table 49. Asia Pacific HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 50. Asia Pacific HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 51. Asia Pacific HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 52. Japan HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 53. Japan HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 54. Japan HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 55. China HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 56. China HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 57. China HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58. India HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 59. India HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 60. India HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 61. Australia HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 62. Australia HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 63. Australia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 64. South Korea HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 65. South Korea HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 66. South Korea HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67. Thailand HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 68. Thailand HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 69. Thailand HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 70. Latin America HPV associated disorders market, by country, 2021 - 2033 (USD Billion)
  • Table 71. Latin America HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 72. Latin America HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 73. Latin America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 74. Brazil HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 75. Brazil HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 76. Brazil HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 77. Argentina HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 78. Argentina HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 79. Argentina HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 80. Middle East & Africa HPV associated disorders market, by country, 2021 - 2033 (USD Billion)
  • Table 81. Middle East & Africa HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 82. Middle East & Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 83. Middle East & Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 84. South Africa HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 85. South Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 86. South Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87. Saudi Arabia HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 88. Saudi Arabia HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 89. Saudi Arabia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 90. UAE HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 91. UAE HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 92. UAE HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 93. Kuwait HPV associated disorders market, by type, 2021 - 2033 (USD Billion)
  • Table 94. Kuwait HPV associated disorders market, by treatment, 2021 - 2033 (USD Billion)
  • Table 95. Kuwait HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 HPV associated disorders market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 HPV associated disorders market dynamics
  • Fig. 11 HPV associated disorders market: Porter's five forces analysis
  • Fig. 12 HPV associated disorders market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Billion)
  • Fig. 14 Cervical intraepithelial neoplasia (CIN) market, 2021 - 2033 (USD Billion)
  • Fig. 15 Cervical cancer market, 2021 - 2033 (USD Billion)
  • Fig. 16 Anal intraepithelial neoplasia (AIN) market, 2021 - 2033 (USD Billion)
  • Fig. 17 Anal cancer market, 2021 - 2033 (USD Billion)
  • Fig. 18 Genital warts market, 2021 - 2033 (USD Billion)
  • Fig. 19 Others market, 2021 - 2033 (USD Billion)
  • Fig. 20 Treatment market, 2021 - 2033 (USD Billion)
  • Fig. 21 Vaccines market, 2021 - 2033 (USD Billion)
  • Fig. 22 Anti-viral drugs market, 2021 - 2033 (USD Billion)
  • Fig. 23 Others market, 2021 - 2033 (USD Billion)
  • Fig. 24 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 25 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 26 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 27 Others market, 2021 - 2033 (USD Billion)
  • Fig. 28 HPV associated disorders market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 37 Europe HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 42 France country dynamics
  • Fig. 43 France HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 54 Asia Pacific HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 57 China country dynamics
  • Fig. 58 China HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 59 India country dynamics
  • Fig. 60 India HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 67 Latin America HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 72 MEA HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait HPV associated disorders market, 2021 - 2033 (USD Billion)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework